The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study
Translational Psychiatry August 10, 2021 D. Quattrone, U. Reininghaus, A. Richards et al.
Genetic risk for schizophrenia and cannabis use each contribute to specific symptom patterns across psychotic disorders, not just diagnostic categories. Among 617 first-episode psychosis patients, higher schizophrenia polygenic risk scores were linked to more severe negative and positive symptoms, regardless of diagnosis. In 979 controls, the same genetic risk was associated with all dimensions of psychotic experiences. Daily or current cannabis use was tied to more positive symptoms in both patients and controls, beyond the effect of genetic risk. The findings support a dimensional view of psychosis, where genetic liability relates to symptom severity and cannabis use specifically increases positive symptoms.